Cannabis regulatory science: risk-benefit considerations for mental disorders

被引:31
作者
Borodovsky, Jacob T. [1 ,2 ]
Budney, Alan J. [1 ]
机构
[1] Dartmouth Geisel Sch Med, Ctr Technol & Behav Hlth, Lebanon, NH USA
[2] Dartmouth Geisel Sch Med, Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA
基金
美国国家卫生研究院;
关键词
Cannabis; marijuana; legalization; mental disorders; psychiatric; regulatory science; NATIONAL EPIDEMIOLOGIC SURVEY; MEDICAL MARIJUANA LAWS; HIGH-POTENCY CANNABIS; SUBSTANCE USE DISORDERS; TOBACCO INDUSTRY; PSYCHIATRIC-DISORDERS; MOOD DISORDERS; UNITED-STATES; PUBLIC-HEALTH; ORAL DELTA(9)-TETRAHYDROCANNABINOL;
D O I
10.1080/09540261.2018.1454406
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
The evolving legal cannabis landscape in the US continues to present novel regulatory challenges that necessitate the development of a Cannabis Regulatory Science. Two specific issues of concern within Cannabis Regulatory Science are (1) the impact that cannabis use has on the incidence, prevalence, and severity of mental disorders, and (2) how cannabis laws and regulations modify this impact. This paper first provides several conceptual points that are useful for evaluating the relationship between cannabis use and mental disorders. Second, it selectively reviews and comments on data relevant to the relationship between cannabis use and depression, several forms of anxiety, post-traumatic stress disorder, schizophrenia, and bipolar disorder. Next, regulatory and public health parallels between the nascent cannabis industry and the pharmaceutical, tobacco, and alcohol industries are discussed. The focus is on specific types of industry practices that may harm those with or at risk for mental disorders. Recommendations are then offered for legal cannabis regulations that could mitigate this harm. Last, future research goals are discussed for building the field of Cannabis Regulatory Science and addressing the potential negative impact of cannabis on those with mental disorders.
引用
收藏
页码:183 / 202
页数:20
相关论文
共 194 条
[1]  
AbbVie Inc, 2018, MAR DRON
[2]   Prospectively Surveying Health-Related Quality of Life and Symptom Relief in a Lot-Based Sample of Medical Cannabis-Using Patients in Urban Washington State Reveals Managed Chronic Illness and Debility [J].
Aggarwal, S. K. ;
Carter, G. T. ;
Sullivan, M. D. ;
Zumbrunnen, C. ;
Morrill, R. ;
Mayer, J. D. .
AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE, 2013, 30 (06) :523-531
[3]   Rates of psychiatric comorbidity among US residents with lifetime cannabis dependence [J].
Agosti, V ;
Nunes, E ;
Levin, F .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2002, 28 (04) :645-654
[4]   Major depressive disorder, suicidal thoughts and behaviours, and cannabis involvement in discordant twins: a retrospective cohort study [J].
Agrawal, Arpana ;
Nelson, Elliot C. ;
Bucholz, Kathleen K. ;
Tillman, Rebecca ;
Grucza, Richard A. ;
Statham, Dixie J. ;
Madden, Pamela A. F. ;
Martin, Nicholas G. ;
Heath, Andrew C. ;
Lynskey, Michael T. .
LANCET PSYCHIATRY, 2017, 4 (09) :706-714
[5]   The Role of Menthol in Cigarettes as a Reinforcer of Smoking Behavior [J].
Ahijevych, Karen ;
Garrett, Bridgette E. .
NICOTINE & TOBACCO RESEARCH, 2010, 12 :S110-S116
[6]   Increasing off-label use of antipsychotic medications in the United States, 1995-2008 [J].
Alexander, G. C. ;
Gallagher, S. A. ;
Mascola, A. ;
Moloney, R. M. ;
Stafford, R. S. .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2011, 20 (02) :177-184
[7]   Marketing of menthol cigarettes and consumer perceptions: a review of tobacco industry documents [J].
Anderson, Stacey J. .
TOBACCO CONTROL, 2011, 20 :II20-II28
[8]  
[Anonymous], 2016, 2016 WARN LETT TEST
[9]  
[Anonymous], 2018, FDAS SENT IN
[10]   Marketing to the marginalised: tobacco industry targeting of the homeless and mentally ill [J].
Apollonio, DE ;
Malone, RE .
TOBACCO CONTROL, 2005, 14 (06) :409-415